Table 1.

Clinical, endoscopic, and histologic features between histologically active and inactive EoE study subjects

	Active EoE ≥15 eos/hpf (n = 91)	Inactive EoE <15 eos/hpf (n = 56)	p*
Age (mean years ± SD)	36.1 ± 13.4	38.5 ± 12.3	0.247
Male (n, %)	52 (57)	31 (55)	0.83
White (n, %)	87 (96)	54 (96)	0.81
College education of higher (n, %)	45 (60)	32 (61)	0.72
Atopy (n, %)
Asthma	24 (32)	21 (47)	0.26
Eczema	21 (28)	10 (22)	0.19
Food allergy	44 (59)	26 (59)	0.88
Allergic rhinitis	52 (69)	34 (76)	0.66
Symptom length >5 years prior to dx (n, %)	57 (63)	35 (63)	0.64
Dysphagia severity (mean Likert score ± SD)	3.2 ± 2.7	1.9 ± 2.3	0.003
Current treatments (n, %)
Any PPI**	35 (40)	35 (67)	0.002
Oral viscous budesonide	30 (34)	21 (38)	0.68
Fluticasone	5 (6)	10 (18)	0.02
Targeted elimination	17 (19)	9 (16)	0.67
Empiric elimination	20 (22)	13 (23)	0.89
Foods eliminated (mean number ± SD)	4.6 ± 2.2	5.6 ± 2.7	0.16
No treatment (not counting PPI)	21 (23)	8 (14)	0.18
Endoscopic features (n, %)
Exudates	57 (63)	6 (11)	< 0.001
Rings	71 (78)	28 (50)	< 0.001
Edema	52 (57)	2 (4)	< 0.001
Furrows	78 (86)	7 (13)	< 0.001
Stricture	44 (48)	16 (29)	0.02
Diameter (mean mm ± SD)	10.4 ± 5.0	13.5 ± 4.8	0.04
Narrowing	32 (35)	13 (23)	0.13
Crepe-paper	4 (4)	1 (2)	0.40
Dilation performed	46 (51)	23 (42)	0.31
Total EREFS score (mean ± SD)	3.8 ± 2.1	1.0 ± 1.0	< 0.001
Inflammatory EREFS scores	2.3 ± 1.4	0.3 ± 0.5	< 0.001
Fibrosis EREFS score	1.7 ± 1.1	0.8 ± 0.9	< 0.001
Peak eosinophil count (mean eos/hpf ± SD)	64.6 ± 47.8	2.9 ± 4.0	--

^*Means compared with a two-sample t-test and proportions compared with a chi square test.

^**PPI treatment status information available for n=132 subjects.